Evidence map›Paper›PMID 25037119›Full record

ArticleThe International journal on drug policy2015

Perceptions of genetic testing and genomic medicine among drug users.

David C Perlman, Camila Gelpí-Acosta, Samuel R Friedman, Ashly E Jordan, Holly Hagan

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The International journal on drug policy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

David C PerlmanMount Sinai Beth Israel, 120 East 16th Street, Floor 12, New York, NY 10003, USA. Electronic address: dperlman@chpnet.org.
Camila Gelpí-AcostaNational Research and Development Institutes, Inc, 71 West 23rd Street, Floor 8, New York, NY 10010, USA.
Samuel R FriedmanNational Research and Development Institutes, Inc, 71 West 23rd Street, Floor 8, New York, NY 10010, USA.
Ashly E JordanNew York University College of Nursing, 726 Broadway, Floor 10, New York, NY 10003, USA.
Holly HaganNew York University College of Nursing, 726 Broadway, Floor 10, New York, NY 10003, USA.
National Development and Research Institutes · USNew York University · USMount Sinai Beth Israel · US

Funding

Transdisciplinary Theoretical Svnthesis and Development CoreP30DA011041 · NIDA · NEW YORK UNIVERSITY · PI Holly Hagan · 1998 to 2026
$38.9M
BEHAVIORAL SCI TRAINING IN DRUG ABUSE RESEARCHT32DA007233 · NIDA · PUBLIC HEALTH SOLUTIONS · PI GOLDSAMT, LLOYD A · 1985 to 2023
$20.2M
Hepatitis Care Coordination in Methadone TreatmentR01DA020841 · NIDA · BETH ISRAEL MEDICAL CTR (NEW YORK) · PI PERLMAN, DAVID C · 2006 to 2010
$1.7M
NIDA NIH HHS P30 DA 011041NIDA NIH HHS P30 DA011041NIDA NIH HHS R01 DA020841NIDA NIH HHS T32 DA007233
6 · The paper itself

Abstract

backgroundGenetic testing will soon enter care for human immunodeficiency virus (HIV) and hepatitis C virus (HCV), and for addiction. There is a paucity of data on how to disseminate genetic testing into healthcare for marginalized populations. We explored drug users' perceptions of genetic testing.

methodsSix focus groups were conducted with 34 drug users recruited from syringe exchange programmes and an HIV clinic between May and June 2012. Individual interviews were conducted with participants reporting previous genetic testing.

resultsAll participants expressed acceptance of genetic testing to improve care, but most had concerns regarding confidentiality and implications for law enforcement. Most expressed more comfort with genetic testing based on individual considerations rather than testing based on race/ethnicity. Participants expressed comfort with genetic testing in medical care rather than drug treatment settings and when specifically asked permission, with peer support, and given a clear rationale.

conclusionAlthough participants understood the potential value of genetic testing, concerns regarding breaches in confidentiality and discrimination may reduce testing willingness. Safeguards against these risks, peer support, and testing in medical settings based on individual factors and with clear rationales provided may be critical in efforts to promote acceptance of genetic testing among drug users.

Indexed as

AdolescentAdultConfidentialityDrug UsersFemaleFocus GroupsGenetic TestingGenomicsHIV InfectionsHumansMaleMiddle AgedNeedle-Exchange ProgramsPerceptionSocial MarginalizationSubstance Abuse, IntravenousDrug usersGenetic testingHCVHIVPerceptionsRacial/ethnic minorities

Identifiers

PMID25037119
PMCPMC4276555
OpenAlexW2064270964

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.